891782-60-8,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.891782-60-8,7-Bromo-3,4-dihydro-2H-isoquinolin-1-one,as a common compound, the synthetic route is as follows.
Compound WXBB-2 (200.00 mg, 884.68 mumol, 1.00 eq), compound WX010-2 (200.00 mg, 1.64 mmol, 1.85 eq), 8-hydroxyquinoline (30.00 mg, 206.67 mumol, 35.71 muL, 0.23 eq) and potassium carbonate (160.00 mg, 1.16 mmol, 1.31 eq) were dissolved in dimethyl sulfoxide (2.00 mL), and cuprous iodide (40.00 mg, 210.03 mumol, 0.24 eq) was added. The system was stirred at 130 C. for 20 hours under nitrogen condition. The reaction solution was cooled to room temperature, added with water (30 mL), and extracted with dichloromethane (30 mL*2). The organic phase was washed successively with water (300 mL) and saturated brine (300 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was dried on a rotary evaporator under reduced pressure to obtain a crude product. The crude product was separated and purified by a TLC (DCM/MeOH=10/1) plate. Compound WX010-3 was obtained, MS m/z: 268.1 [M+H]+.
The synthetic route of 891782-60-8 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; FUJIAN COSUNTER PHARMACEUTICAL CO., LTD.; Wu, Chengde; Yu, Tao; Li, Ning; Chen, Shuhui; US2019/375728; (2019); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem